| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ashwin A Patkar, Prakash S Masand, Stan Krulewicz, Paolo Mannelli, Kathleen Peindl, Katherine L Beebe, Wei Jian. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. The American journal of medicine. vol 120. issue 5. 2007-05-22. PMID:17466657. |
we investigated the efficacy and tolerability of paroxetine controlled release, a selective serotonin reuptake inhibitor in fibromyalgia. |
2007-05-22 |
2023-08-12 |
Not clear |
| G F Aragão, L M V Carneiro, A P F Junior, L C Vieira, P N Bandeira, T L G Lemos, G S de B Vian. A possible mechanism for anxiolytic and antidepressant effects of alpha- and beta-amyrin from Protium heptaphyllum (Aubl.) March. Pharmacology, biochemistry, and behavior. vol 85. issue 4. 2007-05-09. PMID:17207523. |
however, the antidepressant amy effects were not altered by the previous administration of paroxetine, a selective blocker of serotonin uptake. |
2007-05-09 |
2023-08-12 |
mouse |
| Arturo Zazpe, Inés Artaiz, Luis Labeaga, María Luisa Lucero, Aurelio Orjale. Reversal of learned helplessness by selective serotonin reuptake inhibitors in rats is not dependent on 5-HT availability. Neuropharmacology. vol 52. issue 3. 2007-05-01. PMID:17141811. |
in the rat learned helplessness (lh) paradigm, a valid animal model of human depression, repeated treatment with the 5-ht(1a) receptor agonist 8-oh-dpat (0.125 and 0.5mg/kg) and several classes of antidepressants such as the tricyclic agent desipramine (30 and 60mg/kg), the monoamine oxidase inhibitor (maoi) pargyline (60mg/kg) and the ssris fluoxetine (15 and 30mg/kg), paroxetine (15 and 30mg/kg) and sertraline (30mg/kg) improved behavioural deficit in helpless rats. |
2007-05-01 |
2023-08-12 |
human |
| Jan Booij, Jan de Jong, Kora de Bruin, Remco Knol, Maartje M L de Win, Berthe L F van Eck-Smi. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 48. issue 3. 2007-04-24. PMID:17332612. |
quantification of striatal dopamine transporters with 123i-fp-cit spect is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. |
2007-04-24 |
2023-08-12 |
human |
| Liza Leventhal, Valerie Smith, Geoffrey Hornby, Terrance H Andree, Michael R Brandt, Kathryn E Roger. Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain. The Journal of pharmacology and experimental therapeutics. vol 320. issue 3. 2007-04-09. PMID:17142646. |
known selective ne and 5-ht reuptake inhibitors reboxetine, desipramine, fluoxetine, and paroxetine were evaluated in both in vitro and in vivo assays. |
2007-04-09 |
2023-08-12 |
Not clear |
| Kenji Hashimoto, Yuko Fujita, Masaomi Iy. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 3. 2007-04-05. PMID:16495935. |
this study was undertaken to examine the effects of the selective serotonin reuptake inhibitors fluvoxamine and paroxetine on cognitive deficits in mice after repeated administration of the n-methyl-d-aspartate receptor antagonist phencyclidine (pcp). |
2007-04-05 |
2023-08-12 |
mouse |
| Yujiro Kaneko, Atsushi Kashiwa, Takashi Ito, Sumikazu Ishii, Asami Umino, Toru Nishikaw. Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 3. 2007-04-05. PMID:16738540. |
selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine. |
2007-04-05 |
2023-08-12 |
mouse |
| Yujiro Kaneko, Atsushi Kashiwa, Takashi Ito, Sumikazu Ishii, Asami Umino, Toru Nishikaw. Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 3. 2007-04-05. PMID:16738540. |
to obtain an insight into the development of a new pharmacotherapy that prevents the treatment-resistant relapse of psychostimulant-induced psychosis and schizophrenia, we have investigated in the mouse the effects of selective serotonin reuptake inhibitors (ssri), fluoxetine (flx) and paroxetine (prx), on the established sensitization induced by methamphetamine (map), a model of the relapse of these psychoses, because the modifications of the brain serotonergic transmission have been reported to antagonize the sensitization phenomenon. |
2007-04-05 |
2023-08-12 |
mouse |
| Lewis A Opler, Michelle S Grennan, Mark G Ople. Pharmacotherapy of post-traumatic stress disorder. Drugs of today (Barcelona, Spain : 1998). vol 42. issue 12. 2007-04-04. PMID:17285153. |
the selective serotonin reuptake inhibitors (ssris), in particular sertraline and paroxetine, have emerged as the treatment of choice for trauma victims experiencing these three symptom clusters. |
2007-04-04 |
2023-08-12 |
Not clear |
| Mostafa El Mansari, Ove Wiborg, Ouissame Mnie-Filali, Nadia Benturquia, Connie Sánchez, Nasser Haddjer. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. The international journal of neuropsychopharmacology. vol 10. issue 1. 2007-03-30. PMID:16448580. |
using in-vitro binding assays at membranes from cos-1 cells expressing the human 5-ht transporter (hsert) and in-vivo electrophysiological and microdialysis techniques in rats, the present study was directed at determining whether r-citalopram modifies the action of selective serotonin reuptake inhibitors (ssris) known to act on allosteric sites namely escitalopram, and to a lesser extent paroxetine, compared to fluoxetine, which has no affinity for these sites. |
2007-03-30 |
2023-08-12 |
human |
| Mostafa El Mansari, Ove Wiborg, Ouissame Mnie-Filali, Nadia Benturquia, Connie Sánchez, Nasser Haddjer. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. The international journal of neuropsychopharmacology. vol 10. issue 1. 2007-03-30. PMID:16448580. |
in-vitro binding studies showed that r-citalopram attenuated the association rates of escitalopram and paroxetine to the 5-ht transporter, but had no effect on the association rates of fluoxetine, venlafaxine or sertraline. |
2007-03-30 |
2023-08-12 |
human |
| Mostafa El Mansari, Ove Wiborg, Ouissame Mnie-Filali, Nadia Benturquia, Connie Sánchez, Nasser Haddjer. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. The international journal of neuropsychopharmacology. vol 10. issue 1. 2007-03-30. PMID:16448580. |
attenuated the increase of extracellular levels of 5-ht ([5-ht]ext) in the ventral hippocampus induced by both escitalopram (0.28 microm) and paroxetine (0.75 microm), but not fluoxetine (10 microm). |
2007-03-30 |
2023-08-12 |
human |
| Mostafa El Mansari, Ove Wiborg, Ouissame Mnie-Filali, Nadia Benturquia, Connie Sánchez, Nasser Haddjer. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. The international journal of neuropsychopharmacology. vol 10. issue 1. 2007-03-30. PMID:16448580. |
in conclusion, the present in-vitro and in-vivo studies show that r-citalopram counteracts the activity of escitalopram and paroxetine, but not fluoxetine, by acting at the allosteric binding site of the 5-ht transporter, either located in the dorsal raphe nucleus or post-synaptically in the ventral hippocampus. |
2007-03-30 |
2023-08-12 |
human |
| Pierre Blier, Elise Saint-André, Chantal Hébert, Claude de Montigny, Normand Lavoie, Guy Debonne. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. The international journal of neuropsychopharmacology. vol 10. issue 1. 2007-03-30. PMID:16690005. |
paroxetine, both regimens of venlafaxine, and to a lesser extent desipramine significantly decreased whole-blood 5-ht content. |
2007-03-30 |
2023-08-12 |
human |
| Pierre Blier, Elise Saint-André, Chantal Hébert, Claude de Montigny, Normand Lavoie, Guy Debonne. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. The international journal of neuropsychopharmacology. vol 10. issue 1. 2007-03-30. PMID:16690005. |
venlafaxine and paroxetine acted as potent 5-ht reuptake inhibitors in the present study. |
2007-03-30 |
2023-08-12 |
human |
| Jordanna E Bermack, Guy Debonne. Effects of OPC-14523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors. Journal of psychopharmacology (Oxford, England). vol 21. issue 1. 2007-03-16. PMID:16533864. |
we have previously demonstrated that opc produces an increase in 5-ht neurotransmission and a decreased response of 5-ht neurons to the acute administration of paroxetine in the drn, an effect that appears to be mediated by opc's 5-ht1a receptor affinity. |
2007-03-16 |
2023-08-12 |
rat |
| Dawson W Hedges, Bruce L Brown, David A Shwalb, Kirk Godfrey, A Manja Larche. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. Journal of psychopharmacology (Oxford, England). vol 21. issue 1. 2007-03-16. PMID:16714326. |
pubmed and psychinfo electronic databases were searched for social anxiety disorder, social phobia, selective serotonin reuptake inhibitors, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline. |
2007-03-16 |
2023-08-12 |
human |
| Sheldon H Preskorn, Rozina Shah, Melissa Neff, Amanda L Golbeck, Joe Cho. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. Journal of psychiatric practice. vol 13. issue 1. 2007-03-13. PMID:17242587. |
because of substantial inhibition of one or more cytochrome p450 (cyp) enzymes at therapeutic doses, the selective serotonin reuptake inhibitors fluoxetine, fluvoxamine, and paroxetine have a higher risk of cyp-mediated ddis than citalopram, escitalopram, and sertraline, which do not substantially inhibit any cyp enzyme. |
2007-03-13 |
2023-08-12 |
Not clear |
| Yoshimoto Sekine, Katsuaki Suzuki, P Veeraraghavan Ramachandran, Thomas P Blackburn, Charles R Ashb. Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse (New York, N.Y.). vol 61. issue 2. 2007-03-02. PMID:17117425. |
we examined the effect of the administration of the selective serotonin reuptake inhibitors (ssris) fluoxetine, citalopram, and paroxetine on the activity of spontaneously active dopamine (da) neurons in the substantia nigra pars compacta (snc) and ventral tegmental area (vta) in anesthetized adult male sprague-dawley rats. |
2007-03-02 |
2023-08-12 |
rat |
| Chi-Un Pae, Ashwin A Patka. Paroxetine: current status in psychiatry. Expert review of neurotherapeutics. vol 7. issue 2. 2007-02-27. PMID:17286545. |
paroxetine is a selective serotonin reuptake inhibitor (ssri) with antidepressant and anxiolytic properties. |
2007-02-27 |
2023-08-12 |
Not clear |